Literature DB >> 25144629

Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.

Yu-Heng Vivian Ma1, Ann V Schwartz, Sigurdur Sigurdsson, Trisha F Hue, Thomas F Lang, Tamara B Harris, Clifford J Rosen, Eric Vittinghoff, Gudny Eiriksdottir, Alda M Hauksdottir, Kristin Siggeirsdottir, Gunnar Sigurdsson, Diana Oskarsdottir, Nicola Napoli, Lisa Palermo, Vilmundur Gudnason, Xiaojuan Li.   

Abstract

CONTEXT: Osteocyte activity is crucial to the maintenance of bone quality. Sclerostin, an osteocyte product, inhibits bone formation, yet higher circulating sclerostin is associated with higher bone density. Bone marrow fat (MF) is associated with osteoporosis, but little is known about the relationship between osteocyte activity and MF.
OBJECTIVE: Our objective was to assess the relationships between circulating sclerostin, vertebral MF, volumetric bone mineral density (vBMD), and other fat depots in older adults. DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional study in the Age Gene/Environment Susceptibility-Reykjavik cohort. MAIN OUTCOME MEASURES: Outcome measures included vertebral MF (L1-L4) measured with magnetic resonance spectroscopy and vBMD (spine and hip) and abdominal fat measured with quantitative computed tomography.
RESULTS: After excluding subjects with bone-active medication use (n = 50), inadequate serum (n = 2), or inadequate magnetic resonance spectroscopy (n = 1), analyses included 115 men and 134 women (mean age 79 y, mean body mass index 27.7 kg/m(2)). In men, but not women, vertebral MF was greater in those with higher serum sclerostin levels. MF was 52.2 % in the lowest tertile of serum sclerostin and 56.3% in the highest tertile in men (P for trend <.01) in models adjusted for age, body mass index, and diabetes. Sclerostin was positively associated with cortical and trabecular total hip vBMD, weight in men and women, and total fat mass in men but was not associated with total lean mass or abdominal fat depots.
CONCLUSION: Circulating sclerostin levels are associated with higher vertebral marrow fat in men, suggesting a relationship between osteocyte function and marrow adipogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25144629      PMCID: PMC4255105          DOI: 10.1210/jc.2013-4493

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation.

Authors:  James F Griffith; David K W Yeung; Gregory E Antonio; Samuel Y S Wong; Timothy C Y Kwok; Jean Woo; Ping C Leung
Journal:  Radiology       Date:  2006-10-19       Impact factor: 11.105

2.  Increasing sex difference in bone strength in old age: The Age, Gene/Environment Susceptibility-Reykjavik study (AGES-REYKJAVIK).

Authors:  Gunnar Sigurdsson; Thor Aspelund; Milan Chang; Birna Jonsdottir; Sigurdur Sigurdsson; Gudny Eiriksdottir; Adalsteinn Gudmundsson; Tamara B Harris; Vilmundur Gudnason; Thomas F Lang
Journal:  Bone       Date:  2006-06-21       Impact factor: 4.398

3.  Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies.

Authors:  P Meunier; J Aaron; C Edouard; G Vignon
Journal:  Clin Orthop Relat Res       Date:  1971-10       Impact factor: 4.176

4.  Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures.

Authors:  Neil Binkley; D Krueger; R Gangnon; H K Genant; M K Drezner
Journal:  Osteoporos Int       Date:  2005-04-15       Impact factor: 4.507

5.  Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms.

Authors:  Jennifer A Kennell; Ormond A MacDougald
Journal:  J Biol Chem       Date:  2005-04-22       Impact factor: 5.157

6.  Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy.

Authors:  James F Griffith; David K W Yeung; Gregory E Antonio; Francis K H Lee; Athena W L Hong; Samuel Y S Wong; Edith M C Lau; Ping Chung Leung
Journal:  Radiology       Date:  2005-07-29       Impact factor: 11.105

7.  Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women.

Authors:  F A Syed; M J Oursler; T E Hefferanm; J M Peterson; B L Riggs; S Khosla
Journal:  Osteoporos Int       Date:  2008-02-15       Impact factor: 4.507

Review 8.  Marrow fat and the bone microenvironment: developmental, functional, and pathological implications.

Authors:  Clifford J Rosen; Cheryl Ackert-Bicknell; Juan Pablo Rodriguez; Ana Maria Pino
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

9.  Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells.

Authors:  Weimin Qiu; Tom E Andersen; Jens Bollerslev; Susanne Mandrup; Basem M Abdallah; Moustapha Kassem
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

10.  Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice.

Authors:  Jianquan Chen; Yu Shi; Jenna Regan; Kannan Karuppaiah; David M Ornitz; Fanxin Long
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

View more
  25 in total

1.  Reliable quantification of marrow fat content and unsaturation level using in vivo MR spectroscopy.

Authors:  Kaipin Xu; Sigurdur Sigurdsson; Vilmundur Gudnason; Trisha Hue; Ann Schwartz; Xiaojuan Li
Journal:  Magn Reson Med       Date:  2017-07-16       Impact factor: 4.668

Review 2.  Regulation of Skeletal Homeostasis.

Authors:  Mone Zaidi; Tony Yuen; Li Sun; Clifford J Rosen
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

3.  Bone cells and bone turnover in diabetes mellitus.

Authors:  Mishaela R Rubin
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

Review 4.  The emerging role of bone marrow adipose tissue in bone health and dysfunction.

Authors:  Thomas H Ambrosi; Tim J Schulz
Journal:  J Mol Med (Berl)       Date:  2017-11-03       Impact factor: 4.599

5.  Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.

Authors:  Soohyun P Kim; Julie L Frey; Zhu Li; Priyanka Kushwaha; Meredith L Zoch; Ryan E Tomlinson; Hao Da; Susan Aja; Hye Lim Noh; Jason K Kim; Mehboob A Hussain; Daniel L J Thorek; Michael J Wolfgang; Ryan C Riddle
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

6.  Connecting Bone and Fat: The Potential Role for Sclerostin.

Authors:  Heather Fairfield; Clifford J Rosen; Michaela R Reagan
Journal:  Curr Mol Biol Rep       Date:  2017-04-18

7.  The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.

Authors:  Heather Fairfield; Carolyne Falank; Elizabeth Harris; Victoria Demambro; Michelle McDonald; Jessica A Pettitt; Sindhu T Mohanty; Peter Croucher; Ina Kramer; Michaela Kneissel; Clifford J Rosen; Michaela R Reagan
Journal:  J Cell Physiol       Date:  2017-06-06       Impact factor: 6.384

8.  Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity.

Authors:  Gina N Woods; Susan K Ewing; Sigurdur Sigurdsson; Deborah M Kado; Joachim H Ix; Trisha F Hue; Gudny Eiriksdottir; Kaipin Xu; Vilmundur Gudnason; Thomas F Lang; Eric Vittinghoff; Tamara B Harris; Clifford J Rosen; Xiaojuan Li; Ann V Schwartz
Journal:  J Bone Miner Res       Date:  2018-08-27       Impact factor: 6.741

Review 9.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

10.  Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots.

Authors:  Keertik Fulzele; Forest Lai; Christopher Dedic; Vaibhav Saini; Yuhei Uda; Chao Shi; Padrig Tuck; Jenna L Aronson; Xiaolong Liu; Jordan M Spatz; Marc N Wein; Paola Divieti Pajevic
Journal:  J Bone Miner Res       Date:  2017-01-05       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.